Marshall Wace
ONCT

Marshall Wace’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Marshall Wace’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-980
Closed -$44K – 4223
2021
Q4 		$44K Buy
+980
New +$65.9K ﹤0.01% 3586

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's ONCT Position: Q1 2022 in Review

Marshall Wace sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 980 shares — an estimated $44K sold.

Marshall Wace first reported a position in ONCT in Q4 2021 and held it in 1 quarter. The position peaked at $44K in Q4 2021. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Marshall Wace reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 980 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $44K.
  • Marshall Wace first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Marshall Wace's Oncternal Therapeutics, Inc. Common Stock position peaked at $44K in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.